Skip to main content
SpringerLink
Log in

Klinik, Diagnostik, Therapie

Primär kutane Lymphome

  • Zertifizierte Fortbildung
  • Primär kutane Lymphome
  • Published:
hautnah dermatologie Aims and scope

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Abb. 1

© LMU München

Abb. 2

© LMU München

Abb. 3

© LMU München

Abb. 4

© LMU München

Abb. 5

© LMU München

Abb. 6

© LMU München

Literaturverzeichnis

  1. Korgavkar K et al. Changing incidence trends of cutaneous T-cell lymphoma. JAMA Dermatol. 2013; 149: 1295-9

  2. Hodak E et al. Mycosis fungoides: HLA class II associations among Ashkenazi and non-Ashkenazi Jewish patients. Br J Dermatol. 2001; 145: 974-80

  3. Dippel E et al. S2k-Leitlinie - Kutane Lymphome Update 2016 - Teil 1: Klassifikation und Diagnostik (ICD10 C82 - C86). J Dtsch Dermatol Ges. 2017; 15: 1266-73

  4. Elder DE et al. WHO classification of skin tumours. International Agency for Research on Cancer ID: gnd/1001130-4. 4th edition. Lyon: International Agency for Research on Cancer (World Health Organization classification of tumours). 2018

  5. Scarisbrick JJ et al. Blood classification and blood response criteria in mycosis fungoides and Sézary-Syndrome using flow cytometry: recommendations from the EORTC cutaneous lymphoma task force. Eur J Cancer. 2018; 93: 47-56

  6. Youn KH et al. TNM classification system for primary cutaneous lymphomas other than mycosis fungoides and Sezary syndrome: a proposal of the International Society for Cutaneous Lymphomas (ISCL) and the Cutaneous Lymphoma Task Force of the European Organization of Research and Treatment of Cancer (EORTC). Blood. 2007; 110: 479-84

  7. Olsen E et al. Revisions to the staging and classification of mycosis fungoides and Sezary syndrome: a proposal of the International Society for Cutaneous Lymphomas (ISCL) and the cutaneous lymphoma task force of the European Organization of Research and Treatment of Cancer (EORTC). Blood. 2007; 110: 1713-22

  8. Willemze R et al. WHO-EORTC classification for cutaneous lymphomas. Blood. 2005; 105: 3768-85

  9. Engels L et al. Manual: Maligne Lymphome. Empfehlung zur Diagnostik, Therapie und Nachsorge (Tumorzentrum München). Kapitel: Kutane Lymphome. 11. Auflage. Zuckschwerdt Verlag. 2019

  10. Flaig MJ et al. Follicular mycosis fungoides. A histopathologic analysis of nine cases. J Cutan Pathol. 2001; 28: 525-30

  11. Scarisbrick JJ et al. Prognostic factors, prognostic indices and staging in mycosis fungoides and Sézary-Syndrome: where are we now? Br J Dermatol. 2014; 170: 1226-36

  12. Willemze R et al. Subcutaneous panniculitis-like T-cell lymphoma: definition, classification, and prognostic factors: an EORTC Cutaneous Lymphoma Group Study of 83 cases. Blood. 2008; 111: 838-45

  13. Schlaak M et al. Allogeneic stem cell transplantation for advanced primary cutaneous T-cell lymphoma: a systematic review. Crit Rev Oncol Hematol. 2013; 85: 21-31

  14. Dippel et al. S2k-Leitlinie - Kutane Lymphome Update 2016 - Teil 2: Therapie und Nachsorge (ICD10 C82 - C86). J Dtsch Dermatol Ges. 2018; 16: 112-23

  15. Nicolay JP et al. Cutaneous B-cell lymphomas - pathogenesis, diagnostic workup, and therapy. J Dtsch Dermatol Ges. 2016; 14: 1207-24

  16. Kim YH et al. Topical nitrogen mustard in the management of mycosis fungoides: update of the Stanford experience. Arch Dermatol. 2003; 139: 165-73

  17. Olsen EA et al. Guidelines for phototherapy of mycosis fungoides and Sezary syndrome: A consensus statement of the United States Cutaneous Lymphoma Consortium. J Am Acad Dermatol. 2016; 74: 27-58

  18. Elsayad K et al. Total Skin Electron Beam for Primary Cutaneous T-cell Lymphoma. Int J Radiat Oncol Biol Phys. 2015; 93: 1077-86

  19. Knobler R et al. Extracorporal Photopheresis - an overview. Front Med. 2018; 5: 236.

  20. Kapser C et al. Treatment of cutaneous T-cell lymphoma with oral aitretinoin. J Eur Acad Dermatol Venereol. 2015; 29: 783-8

  21. Youn KH et al. Mogamulizumab versus vorinostat in previously treated cutaneous T-cell lymphoma (MAVORIC): an international, open-label, randomised, controlled phase 3 trial. Lancet Oncol. 2018; 19: 1192-204

  22. Prince H et al. Brentuximab vedotin or physician's choice in CD30-positive cutaneous T-cell lymphoma (ALCANZA): an international, open-label, randomised, phase 3, multicentre trial. Lancet. 2017; 390: 555-66

  23. Watanabe R et al. Alemtuzumab therapy for leukemiccutaneous T-cell lymphoma: diffuse erythema as a positive predictor of complete remission. JAMA Dermatol. 2014; 150: 776-9

  24. Scarisbrick JJ et al. Cutaneous Lymphoma International Consortium Study of Outcome in Advanced Stages of Mycosis Fungoides and Sézary-Syndrome: Effect of Specific Prognostic Markers on Survival and Development of a Prognostic Model. J Clin Oncol. 2015; 33: 3766-73

  25. Mitteldorf C et al. Folliculotropic mycosis fungoides. J Dtsch Dermatol Ges. 2018; 16: 543-57

Download references

Author information

Authors and Affiliations

  1. Klinik und Poliklinik für Dermatologie und Allergologie, Klinikum der Ludwig-Maximilians-Universität München, Frauenlobstr. 9–11, 80337, München, Germany

    Suzan Stürmer &  Max Schlaak

Authors
  1. Suzan Stürmer
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Max Schlaak
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Suzan Stürmer.

Ethics declarations

Die Autoren erklären, dass sie sich bei der Erstellung des Beitrages von keinen wirtschaftlichen Interessen leiten ließen und dass keine potenziellen Interessenkonflikte vorliegen. Der Verlag erklärt, dass die inhaltliche Qualität des Beitrags von zwei unabhängigen Gutachtern geprüft wurde. Werbung in dieser Zeitschriftenausgabe hat keinen Bezug zur CME-Fortbildung. Der Verlag garantiert, dass die CME-Fortbildung sowie die CME-Fragen frei sind von werblichen Aussagen und keinerlei Produktempfehlungen enthalten. Dies gilt insbesondere für Präparate, die zur Therapie des dargestellten Krankheitsbildes geeignet sind.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Stürmer, S., Schlaak, M. Primär kutane Lymphome. hautnah dermatologie 37, 51–63 (2021). https://doi.org/10.1007/s15012-021-6619-7

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s15012-021-6619-7

Search

Navigation